HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
Investors who purchased securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024, and October 17, 2024, have the opportunity to lead a securities fraud lawsuit. The Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of these purchasers. If you bought Humacyte securities during this time, you might be entitled to compensation without any out-of-pocket fees. To participate in the class action lawsuit, you need to act before January 17, 2025.
According to the lawsuit, defendants allegedly made false statements and failed to disclose issues at Humacyte’s facility in Durham, North Carolina, which led to delays in the FDA’s review of the Biologics License Application. This situation posed a risk to FDA approval of Acellular Tissue Engineered Vessel (“ATEV”) for vascular trauma. When this information became public, investors suffered damages.
If you are interested in joining the Humacyte class action, you can visit the Rosen Law Firm’s website or contact Phillip Kim, Esq. for more information. It is essential to choose qualified counsel with a proven track record in these cases. The Rosen Law Firm has a history of successful securities class actions and shareholder derivative litigation, securing significant settlements for investors.
Remember, no class has been certified yet, so until that happens, you are not represented by counsel unless you choose to hire one. You have the option to remain an absent class member and take no action at this moment. Stay updated on any developments related to this case by following the Rosen Law Firm on social media platforms.